


Estramustine

Chemical Properties

CAS No. :	2998-57-4
Formula:	C ₂₃ H ₃₁ Cl ₂ N ₃ O ₃
Molecular Weight:	440.4
Storage:	Pure form: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Estramustine (LEO-275) is a nitrogen mustard linked to estradiol, usually as phosphate. Estramustine has been used to treat prostatic neoplasms; also has radiation protective properties. Estramustine is selectively taken up by prostate cells and exerts antineoplastic effects by interfering with microtubule dynamics and by reducing plasma levels of testosterone.
Targets(IC50)	Microtubule Associated

Solubility Information

Solubility	DMSO: 250 mg/mL (567.67 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (22.71 mM), Suspension. 10% DMSO+90% Saline: < 10 mg/mL (22.71 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2707 mL	11.3533 mL	22.7066 mL
5 mM	0.4541 mL	2.2707 mL	4.5413 mL
10 mM	0.2271 mL	1.1353 mL	2.2707 mL
50 mM	0.0454 mL	0.2271 mL	0.4541 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. *Drugs Aging*. 1995 Jul;7(1):49-74.
- Zhang C, Jing T, Wang F, Gao X, Xu C, Sun Y. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials. *Actas Urol Esp*. 2014 Apr;38(3):184-91. doi: 10.1016/j.acuro.2013.07.010. Epub 2014 Feb 5. English, Spanish. PubMed PMID: 24507454.
- Nakai Y, Nishimura K, Nakayama M, Uemura M, Takayama H, Nonomura N, Tsujimura A; Osaka CRPC Clinical Study Collaboration. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. *Int J Clin Oncol*. 2014 Feb;19(1):165-72. doi: 10.1007/s10147-013-0536-7. Epub 2013 Mar 1. PubMed PMID: 23456140.
- Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, Yu Y, Yang C, Wang C, Xu T, Xu Z, Zou Q. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2016 Sep;95(39):e4801. doi: 10.1097/MD.0000000000004801. Review. PubMed PMID: 27684806; PubMed Central PMCID: PMC5265899.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481